$CLOV

Clover Health's CEO Just Sold 62,711 Shares for Tax Withholding. The Bigger News Comes Next Week.

Clover Health Investments CEO Andrew Toy sold 62,711 shares of Class A stock on July 15, 2026 for about $292,860 to cover tax withholding tied to RSU vesting, according to an SEC Form 4. He retained about 9.5 million shares (~2% ownership). The article also cites CLOV’s recent court order and a July data breach, with earnings due early August.

Original reporting
Published Jul 31, 2026, 1:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 31, 2026, 2:17 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Clover Health's CEO Just Sold 62,711 Shares for Tax Withholding. The Bigger News Comes Next Week. — source image
Decision brief

The 30-second read

$CLOVNeutralLow
01

Why it matters

The transaction itself is characterized as routine tax withholding, so it is unlikely to change fundamentals. The more actionable catalyst is the upcoming Q2 earnings release in early August and how the market prices the data breach impact.

02

Market read

Traders may treat this as a low-signal insider transaction and instead focus on earnings timing and data-breach remediation updates.

03

What to watch

The article highlights two larger, potentially market-moving items: the June favorable Star-rating court order and the July data breach, with earnings due in early August.

Relevance 4/10Novelty 4/10Timing: insider Form 4 reported today, ahead of early-August Q2 earnings

Background

The piece centers on an SEC Form 4 disclosure for Clover CEO Andrew Toy’s July 15, 2026 sell-to-cover transaction tied to RSU vesting.

Company-level read

Ticker impact

$CLOVNeutralHigh confidence
Context

Clover CEO Andrew Toy sold 62,711 shares via a non-discretionary sell-to-cover for RSU tax withholding, per an SEC Form 4.

Expected impact

Limited near-term impact; any reaction is more likely driven by upcoming earnings and prior data-breach overhang than this Form 4.

Evidence & confidence

The article explicitly states the sale was required for tax withholding on vested RSUs and provides the remaining stake and vesting cadence, reducing interpretive value for valuation changes.

Market effects

Medicare Advantage insurers may continue to face headline risk from compliance and data-security events, which can dominate sentiment versus routine insider transactions.

None indicated.

None indicated.

Counterpoint

Even if sell-to-cover is non-discretionary, repeated vesting-driven sales can still mechanically increase supply and cap upside during thin liquidity windows.

Key entities

  • Clover Health Investments, Corp.

    Medicare Advantage insurer with proprietary Clover Assistant software; subject of the CEO insider sale and upcoming earnings.

  • Andrew Toy

    Clover CEO who sold 62,711 shares for tax withholding associated with RSU vesting.

Related articles

$CLOVMedAI 8/10

Clover Health Investments Q2 Earnings Call Highlights

Clover Health Investments (CLOV) reported Q2 adjusted EBITDA of $41 million and GAAP net income of $28 million. For the first half of 2026, it posted $81 million adjusted EBITDA and $55 million GAAP net income, with $443 million cash and investments and no debt. The company raised 2026 guidance to $2.92B-$3.0B revenue and $70M-$85M adjusted EBITDA, and discussed cohort maturation and 4.5-star ratings for 2027.

$METMed

Financial results round-up: MetLife, Prudential, Corebridge, Palomar, Heritage, TWFG, Root and more

A financial results roundup covers multiple insurers and MGAs. MetLife reported Q2 net income of $705m and adjusted EPS $2.43. Prudential posted Q2 net income of $985m and record individual life sales. Corebridge reported a $16m net loss and merger approval. Palomar, Heritage, TWFG, Root, Trupanion and Clover Health also reported Q2 figures and guidance updates.

$CLOVHighAI 9/10

CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV): Results of Operations and Financial Condition

CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a2q26exx991xearningsrelease.htm EX-99.1 Document Exhibit 99.1 Clover Health Reports Second Quarter 2026 Results Business Highlights: • Delivered strong second quarter 2026 GAAP Net Income alongside continued market-leading Medicare Advantage membership growth • Improved

$CLOVMed

What's Fueling Clover Health's Recent Stock Surge

Clover Health (CLOV) shares rose about 7% to $2.39 after UnitedHealth Group (UNH) reported strong Q1 2026 results and raised its full-year adjusted net earnings outlook to over $18.25 per share, lifting sentiment for health insurers. Clover also cited 53% YoY Medicare Advantage membership growth and reiterated 2026 GAAP net income profitability guidance. Analysts maintain a Hold rating and a $2.90 average target.